Skip to content

Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer

Prevalence and Consequences of Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer: a Prospective Population Based Multicenter Study. The PALN Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06065891
Acronym
PALN
Enrollment
300
Registered
2023-10-04
Start date
2023-09-05
Completion date
2028-09-05
Last updated
2023-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymph Node Metastasis, Pancreas Adenocarcinoma, Pancreas Cancer

Brief summary

Lymph node metastases are a strong prognostic predictor for pancreatic cancer. Para-aortic lymph nodes (PALN) are the final nodes for periampullary cancers before the cancer cells enter the systemic lymphatic circulation. Some consider these nodes to be regional lymph nodes and dissect them as a part of a routine lymphadenectomy for pancreatic cancer. Others argue that metastases to these nodes represent systemic disease and recommend that radical surgery including extended lymphadenectomy should be abandoned. The aim of this study is to define the incidence and clinical consequences of PALN metastasis in patients submitted to a tentative curative resection for carcinoma of the head of the pancreas by systematically resecting paraaortic lymph nodes. Primary outcome 1\) To determine incidence of PALN metastasis in patients submitted to a tentative curative resection Secondary outcomes 1. To determine prognosis of patients with PALN metastasis after a curative resection 2. To determine incidence of metastasis in reginal lymph nodes in patients submitted to a tentative curative resection. 3. To determine prognosis of patients with metastasis in regional lymph nodes in patients submitted to a tentative curative resection. 4. To address the question of how to optimize the frozen section analyses of PALN as related to the final pathology report. 300 patients are planned to be included in the trial.

Detailed description

Lymph node metastases are a strong prognostic predictor for pancreatic cancer. Para-aortic lymph nodes (PALN) (No. 16 nodes) are the final nodes for periampullary cancers before the cancer cells enter the systemic lymphatic circulation. Some consider these nodes to be regional lymph nodes and dissect them as a part of a routine lymphadenectomy for pancreatic cancer. Others argue that metastases to these nodes represent systemic disease and recommend that radical surgery including extended lymphadenectomy should be abandoned. There is no consensus whether to abort the resection if metastases in PALN are discovered pre- or perioperatively. Use of adjuvant and neoadjuvant chemotherapy may further affect the impact of lymph node metastases, including PALN. The aim of this study is to define the incidence and clinical consequences of PALN metastasis in patients submitted to a tentative curative resection for carcinoma of the head of the pancreas by systematically resecting paraaortic lymph nodes. Primary outcome 1\) To determine incidence of PALN metastasis in patients submitted to a tentative curative resection Secondary outcomes 1. To determine prognosis of patients with PALN metastasis after a curative resection 2. To determine incidence of metastasis in reginal lymph nodes in patients submitted to a tentative curative resection. 3. To determine prognosis of patients with metastasis in regional lymph nodes in patients submitted to a tentative curative resection. 4. To address the question of how to optimize the frozen section analyses of PALN as related to the final pathology report. PALN are resected separately and analyzed both as cryo sections and by routine histochemistry. Prevalence of PALN differ markedly from 5% to 30%. Given the descriptive primary endpoint, no rigorous power calculation can be made. Assuming a prevalence of 17% (as reported in a recent series from Stockholm), a hazard ratio for survival ranging from 1,04 to 3,00 and and a drop out of 17%. Complete data is needed for 90 patients but the trial aim to include 300. Resection of PALN is becoming routine at most participating centers in the trial. Therefore, the trial will not alter care for the participating patients in any major way. Rather the trial aims to systematically asses how this altered practice affect patient outcome.

Interventions

PROCEDUREPALN resection

Resection of paraaortic lymph nodes in pancreatic cancer

Sponsors

Jon Unosson
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Resectable suspected periampullary cancer (requiring duodenopancreatectomy) (NCCN guidelines 2020) Borderline resectable periampullary cancer (requiring duodenopancreatectomy) (NCCN guidelines 2020) Age \>18 years Written patient consent

Exclusion criteria

Contraindication for a radical resection procedure Unresectable tumor (NCCN guidelines 2020) or metastatic disease (lgll station 16 not included) Mental or organic disorders which could interfere with giving informed consent or receiving treatments

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of paraaortic lymph nodes in pancreatic cancer in patients submitted to a tentative curative resection5 yearsFrequency of metastases in paraaortic lymph nodes in patients with resectable pancreatic cancer will be assessed by systematically resecting these glands, irrespective of perioperative findings.

Secondary

MeasureTime frameDescription
To determine prognosis of patients with PALN metastasis (lgll station 16) after a curative resection6 yearsOverall survival in years from resection will be measured in patients with and without PALN metastasis
To determine incidence of metastasis in lgll station 8, 9 and 12 in patients submitted to a tentative curative resection.5 yearsFrequency of metastases in lymph node 8, 9 and 12 in patients with resectable pancreatic cancer will be assessed by systematically resecting these glands and placing them i separate vials as opposed to en-bloc with the main specimen in order to determine rate of lymph node metastases.
To determine prognosis of patients with metastasis in lgll station 8, 9 and 12 in patients submitted to a tentative curative resection.6 yearsOverall survival in years from resection will be measured in patients with and without metastases in lymph node stations 8, 9 and 12.
To address the question of how to optimize the frozen section analyses (lgll station 16) as related to the final pathology report?5 yearsOverall survival in years from resection will be measured in patients with and without metastasis in PALN detected on cryosection

Countries

Denmark, Sweden

Contacts

Primary ContactChristopher Månsson
Christopher.mansson@akademiska.se0186110000
Backup ContactBritt-Marie Karlson
britt-marie.karlson@akademiska.se0186110000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026